New research demonstrates Dario's ability to
reduce costs through lower utilization of expensive healthcare
resources, and the winning of a prestigious gold ribbon
award
NEW
YORK, Oct. 17, 2023 /PRNewswire/
-- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the
"Company"), a leader in the global digital health market, announced
today new research presented by Sanofi U.S. at the Academy of
Managed Care Pharmacy's 2023 annual conference Nexus
("AMCP-Nexus"), demonstrating a 36% reduction in 30-day hospital
readmissions for Dario users compared to non-users living with type
2 diabetes.
Research Demonstrates Significant Reductions in Costly
Utilization Metrics
New data presented by Sanofi U.S. at AMCP-Nexus examined matched
Dario users and non-users with type 2 diabetes to understand the
impact of Dario's digital health solution. The research examined
real-world claims data to determine whether users engaged with
Dario's solution demonstrated less costly utilization of
hospital-related utilization and found clinically meaningful
impacts:
- 36% reduction in 30-day hospital readmission rate; and
- 1.6 fewer days in the hospital
The research is part of an ongoing study initiative conducted
jointly by Dario and Sanofi U.S., and complements previously
published studies presented at ISPOR demonstrating Dario's ability
to reduce all-cause healthcare utilization by 9% and inpatient
hospitalizations by 23%.
A panel of independent judges awarded the research the
AMCP-Nexus Gold ribbon award after assessing for relevance,
originality, quality, bias and clarity.
"Our research collaboration with Sanofi U.S. continues to yield
strong results demonstrating the real, measurable value of digital
health for payers. Helping people improve their self-care of
diabetes to such a significant degree that we see a 36% reduction
in 30-day hospital readmissions is an incredible testament to the
power of Dario's highly personalized, consumer-centered digital
health solution," said Omar
Manejwala, M.D., Chief Medical Officer of Dario.
"We are extremely pleased to see the quality of our research
efforts being independently recognized by the Academy of Managed
Care Pharmacy. This recognition is testament to the commitment and
dedication of our team and collaboration with Dario to deliver
scientifically sound evidence to support informed decision-making
in the best interest of patients," said Felix Lee, Medical Head of Digital Healthcare at
Sanofi U.S.
Additional Studies Demonstrate Improvements in Healthcare
Effectiveness Data and Information Set (HEDIS) Measurement Criteria
and Engagement-Related Outcomes
Two additional analyses presented at AMCP Nexus by Sanofi U.S.
examined clinical improvements in the same exact and
propensity-score matched populations of Dario users and non-Dario
users living with Type 2 diabetes.
The first analyzed Dario's ability to support HEDIS quality
measurement criteria for HbA1c control, an important metric for
Medicare and Medicaid health plans. The research showed 9% more
Dario users achieved HbA1c below 8% (control) compared to non-users
after 12 months and 13% less Dario users stayed above 9% (poor
control).
The second examined the association between more
frequent engagement with Dario's digital health solution
and a reduction in HbA1c in adults living with type 2 diabetes,
showing better clinical outcomes with more frequent engagement.
Dario and Sanofi Research: Setting New Standards for
Evidence-Based Digital Health
This research study, conducted by Sanofi, is part of Dario's and
Sanofi's ground-breaking collaboration to set new standards in
digital health research by analyzing real-world digital health data
using the evidence generation principles of a pharmaceutical study.
To read more about this research, click here.
The analyses used HIPAA-complaint deidentified patient data
linking claims data, electronic medical record data and lab data to
construct the study cohorts. All data in these studies was
collected following receipt of all required patient consents.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading digital health
company revolutionizing how people with chronic conditions manage
their health through a user-centric, multi-chronic condition
digital therapeutics platform. Dario's platform and suite of
solutions deliver personalized and dynamic interventions driven by
data analytics and one-on-one coaching for diabetes, hypertension,
weight management, musculoskeletal pain and behavioral health.
Dario's user-centric platform offers people continuous and
customized care for their health, disrupting the traditional
episodic approach to healthcare. This approach empowers people to
holistically adapt their lifestyles for sustainable behavior
change, driving exceptional user satisfaction, retention and
results and making the right thing to do the easy thing to do.
Dario provides its highly user-rated solutions globally to
health plans and other payers, self-insured employers, providers of
care and consumers. To learn more about Dario and its digital
health solutions, or for more information, visit
http://dariohealth.com.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. related thereto contain or may
contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Statements that
are not statements of historical fact may be deemed to be
forward-looking statements. For example, the Company is using
forward-looking statements in this press release when it discusses
the potential benefits realized by the use of its products, and
that the results of the research is a testament to the power of its
highly personalized, consumer-centered digital health solution.
Without limiting the generality of the foregoing, words such as
"plan," "project," "potential," "seek," "may," "will," "expect,"
"believe," "anticipate," "intend," "could," "estimate" or
"continue" are intended to identify forward-looking statements.
Readers are cautioned that certain important factors may affect the
Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for Dario™
as described herein) may differ significantly from those set forth
in the forward-looking statements. The Company undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future events or otherwise,
except as required by applicable law.
DarioHealth Corporate Contact
Mary Mooney
VP Marketing
mary@dariohealth.com
+1-312-593-4280
Media Contact:
Scott
Stachowiak
Scott.Stachowiak@russopartnersllc.com
+1-646-942-5630
Logo -
https://mma.prnewswire.com/media/1920436/DarioHealth_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/new-research-shows-36-reduction-in-30-day-hospital-readmission-rate-for-dario-users-with-type-2-diabetes-301958677.html
SOURCE DarioHealth Corp.
